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BACKGROUND: Repair of various types of DNA damages is critical for genomic stability. DNA-dependent protein kinase (DNA-PK) has
an important role in DNA double-strand break repair. We examined whether there may be a correlation between DNA-PK activity
in peripheral blood lymphocytes (PBLs) and survival percentages in various cancer patients. We also investigated the changes of
DNA-PK activity in PBLs after radiotherapy.
METHODS: A total of 167 of untreated cancer patients participated in this study. Peripheral blood was collected, separated, and
centrifuged. DNA-PK activity was measured by DNA-pull-down assay. Chromosomal aberrations were examined by cytogenetic
methods.
RESULTS: DNA-PK activity of PBLs in advanced cancer patients was significantly lower than that in early stage. The patients with lower
DNA-PK activity in PBLs tended to have the lower disease-specific survivals and distant metastasis-free survivals than those with higher
DNA-PK activity in advanced stages. There was also a tendency of inverse correlation between DNA-PK activity and excess fragments.
The DNA-PK activity of PBLs in most patients decreased in response to radiation as the equivalent whole-body dose increased.
CONCLUSION: Cancer patients in advanced stage, with lower DNA-PK activity of PBLs might have higher distant metastasis and exhibit poorer
prognosis. Therefore, DNA-PK activity in PBLs could be used as a marker to predict the chromosomal instability and poorer prognosis.
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Genomic instability is caused by constant DNA damages of various
types. Of these, DNA double-strand breaks (DSBs) are believed to
be one of the most serious damages induced by DNA damaging
agents. DNA DSB repair has an important role in the maintenance
of genomic stability (Collis et al, 2005).
Non-homologous end-joining (NHEJ) pathway is a prevalent
mechanism for DNA DSB repair (Jeggo and Lavin, 2009). In NHEJ
pathway, DSBs are directly, or after processing of the DNA ends,
rejoined at an appropriate chromosomal end and DNA-dependent
protein kinase (DNA-PK) has a core component of NHEJ (Lees-
Miller, 1996; Jeggo, 1998). It is a serine/threonine kinase,
composed of DNA-PK catalytic subunit (DNA-PKcs) and hetero-
dimer of Ku70 and Ku86. DNA-PK binds DNA DSBs, phosphor-
ylates, and activates DNA-binding proteins, including XRCC4,
DNA ligase IV, p53, and several transcription factors. Subse-
quently, ligase IV reseals DNA DSBs (Jeggo, 1998).
We have previously demonstrated that DNA-PK activity in
peripheral blood lymphocytes (PBLs) is associated with risk of
breast and uterine cervix cancer, thereby rendering it as a marker
to predict the chromosomal instability and risk of such cancers
(Someya et al, 2006).
The PBLs have been our focus of study as they can be obtained
far more easily than other human tissues. A tight correlation of
DNA-PK activity between PBLs and bronchial epithelial cells
(a progenitor cell for lung cancer) that were obtained by
bronchoscopy, suggested that PBLs can be used as a surrogate
cell type for a variety of cells (Auckley et al, 2001).
In this study, we examined whether there may be the relations
between DNA-PK activity in PBLs and survival percentages in
various cancer patients. We also investigated the changes of
DNA-PK activity in PBLs, following radiotherapy as a function of
the equivalent whole-body dose.
MATERIALS AND METHODS
Selection eligibility
All subjects were Japanese. In all, 167 untreated cancer patients,
who were planned to receive radiotherapy at the Sapporo Medical
University, were enrolled in this study. Patients with histories of
other cancer, those treated with radiation or chemotherapy and
those using immunosuppressive medications were excluded.
Patients with breast cancer were all sporadic cases. The study
was approved by the Appropriate Committees for Human Rights
in Research in our hospital, and written informed consent was
obtained from each subject. Individual characteristics of the
patients have been summarised in Table 1. Patients with stage 0, I,
or II were classified into ‘early’ and those with stage III or IV into
‘advanced’.
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sCancer treatment and estimation of radiation doses to PBLs
Breast cancer patients after partial mastectomy received post-
operative irradiation to the conserved breast. Some patients were
also treated with chemotherapy or hormonal therapy following
radiotherapy. In uterine cervix cancer, radiotherapy consisted of
external radiation and intracavitary radiation. Some patients
received chemotherapy during radiotherapy. In cancer of head
and neck, or oesophagus, primary radiotherapy was carried out.
Some patients received chemotherapy during radiotherapy. In case
of non-Hodgkin’s lymphoma, primary radiotherapy was carried
out. One patient received chemotherapy before radiotherapy.
In radiotherapy, the dose per fraction ranged from 1.8 to 2.0Gy.
All treatment regimens included five daily fractions per week.
Several mathematical models have been developed to estimate the
dose to PBLs for each treatment plan. A simple approach is to
calculate the equivalent whole-body dose from the integral dose
(dose irradiated volume), divided by the body weight (Thierens
et al, 1995). The effect of dose fractionation is not taken into
account in this formula. However, it can be used in analysis of our
results, as dose fractionation is constant in all cases.
Blood collection and PBLs separation
Peripheral blood (12ml) was collected with a sterile heparinised
tube from all individuals before radiotherapy began. Blood
samples were also obtained during and after radiotherapy.
Lymphocytes were separated from peripheral blood cells by
lymphoprep (Nycomed Pharma, Zurich, Switzerland), centrifuged
at 1500r.p.m. (300 g) for 30min at 41C, and washed twice with
phosphate-buffer saline.
PBLs lysis, protein extraction, DNA-PK assay
Protein extraction and DNA-PK assay was carried out as described
in our previous publication (Someya et al, 2006). Briefly, PBLs
were thawed with high-salt buffer and the suspension was lysed by
three rounds of freeze-thaw cycle and clarified by centrifugation at
15000r.p.m. (18000 g) for 7min at 41C. Protein concentration
was assayed using a BCA protein assay kit (Thermo Fisher
Scientific Inc., Barrington, IL, USA) with bovine serum albumin as
the standard. The PBLs lysates were diluted to 0.25mgml
 1 with
high-salt buffer. The lysate was mixed with kinase assay buffer,
synthetic peptide hp53-S15 (sequence: EPPLSQEAFADLWKK;
synthesised in Sawady Biotechnology, Tokyo, Japan), and with or
without sonicated salmon sperm DNA.
This reaction mixture was incubated at 371C for 10min and
stopped by the addition of 30% acetic acid. The reaction mixture
(40ml) was absorbed onto a P81 phosphocellulose filter (2.3cm of
diameter, Whatman, Maidstone, UK) and was washed in 15%
acetic acid, and then in 99% ethanol followed by counting in a
liquid scintillation counter. The net phosphorylation of hp53-S15
was calculated as phosphate incorporation in reaction with hp53-
S15 minus that in reaction without hp53-S15 divided by the specific
radioactivity of ATP. DNA-dependent phosphorylation of hp53-S15
is interpreted as DNA-PK activity (Lees-Miller et al,1 9 9 2 ) .
Chromosomal aberrations in PBLs
Spontaneous chromosomal aberrations in PBLs were observed by
Giemsa staining from 30 patients.
Blood samples for measurements of DNA-PK activity were
collected from April 2002 to August 2005. For chromosomal
aberration study, we used these samples of all participants from
December 2002 to March 2004. The procedure has been described
previously (Someya et al, 2006). In all, 200 metaphase cells from
each individual were analysed, and the numbers of excess
fragments were counted. Chromosomal aberrations are typically
subdivided into chromatid breaks and gaps vs chromosome breaks
and gaps, triradials, quadriradials, and dicentrics. Chromosome
breaks and gaps not accompanying a dicentric chromosome were
defined as excess fragments in this analysis. Triradials and
quadriradials were excluded from the current analysis as they
were not observed.
Western blot analysis
Cell extracts were analysed by electrophoresis on 8% polyacryl-
amide SDS gels, transferred to polyvinylidene difluoride membrane,
and probed with a rabbit polyclonal antibody to DNA-PKcs and a
mouse polyclonal antibody to Ku (Someya et al, 2006). Image J 1.39
(free software of National Institutes of Health, Bethesda, MD, USA)
was used to analyse the results of immunoblottings.
Statistical methods
The unpaired t-test was used to compare DNA-PK activity between
groups. All statistical tests were two-sided. Multivariate analysis
was used to clarify significant variables, which correlate with
disease-specific survival or distant metastasis-free survival. The
distant metastasis refers to cancer that has spread from the original
(primary) tumour to distant organs or distant lymph nodes. All
statistical computing was done with StatView version 4.58 (Abacus
Concepts, Berkeley, CA, USA). Survival rates of the patients were
measured using the Kaplan–Meier method. The overall survival
was calculated from the date when the treatment started to the time
of death or last follow-up. The distant metastasis-free survival was
calculated from the date when the treatment started to the time of
diagnosis of distant metastasis or last follow-up. The local control
refers to a state of absence of any disease activity in the primary
tumour. Statistical significance of survivals was compared by the log
rank test.
RESULTS
Figure 1A compared the DNA-PK activity in PBLs of cancer
patients in early and advanced stages before treatment. It was
Table 1 Summary of the characteristics of the patients
Age (years) 55.4 (30–88)
Gender
Male 19
Female 148
Cancer site
Breast 115
Uterine cervix 23
Head and neck 19
Esophagus 6
Non-Hodgkin’s lymphoma 4
Stage
Early (0–II) 134
Advanced (III–IV) 33
Surgery
Yes 129
No 38
Radiation alone 34
Chemotherapy 51
Endocrinetherapy 82
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smeasured as 10.0±5.5pmol (mean±s.d.) and 7.9±3.5pmol,
respectively. DNA-PK activity was found to be significantly lower
in advanced cancer than in early stage (P¼0.007). We obtained a
blood sample from a normal volunteer on 11 other days from
December 2002 to March 2004, and measured the DNA-PK activity
of PBL to examine its intra-individual variability. It was measured
as 15.0±2.8pmol, indicating that DNA-PK activity of PBL may be
relatively constant.
Figure 1B demonstrated disease-specific survival according to
DNA-PK activity of PBLs when cancer patients were divided into
early and advanced stages. Advanced stage patients with high
DNA-PK activity demonstrated 66.7% of 5-year survival rate and
22.5% with low DNA-PK activity. Statistically, there might be a
trend for better survival in high DNA-PK activity (P¼0.05). There
were no such differences observed in early stage patients. The
5-year survival rate was 96.8% with high DNA-PK activity and
98.3% with low DNA-PK activity. We further performed multiple
regression analysis (Table 2). DNA-PK activity, stage, and surgery
showed significant correlation with the disease-specific survival.
No significant differences were found in cancer sites between
breast cancerþmalignant lymphomas and the other sites.
Figure 1C showed the distant metastasis-free survival in regard
to DNA-PK activity of PBLs when cancer patients were divided
into early and advanced stages. The 5-year distant metastasis-free
survival rate in advanced stage patients was 77.8% with high DNA-PK
activity and 34.5% with low DNA-PK activity. The patients with
lower DNA-PK activity in PBLs tended to have the lower distant
metastasis-free survivals than those with higher DNA-PK activity
in advanced stages although the difference was not significant
(P¼0.08). There were no differences in early stage patients that
exhibited 92.1% survival rate with high DNA-PK activity and
95.5% with low DNA-PK activity. We further performed multiple
regression analysis (Table 3). In this analysis, DNA-PK activity,
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Figure 1 (A) DNA-PK activity in PBLs of patients with varied cancer types. Cancer patients were separated into two categories by stage: the early stage
and the advanced stage. The horizontal bar indicates the mean value. (B) Disease-specific survival of cancer patients treated with radiotherapy according to
stage and DNA-PK activity in PBLs. ‘Early high DNA-PK’ included 65 patients; ‘early low DNA-PK’ included 69 patients; ‘advanced high DNA-PK’ included
9 patients; ‘advanced low DNA-PK’ included 24 patients. (C) Distant metastasis-free survival of cancer patients treated with radiotherapy according to stage
and DNA-PK activity in PBLs. (D) Correlation between chromosomal aberrations and DNA-PK activity of PBLs. The number of excess fragments in 200
mitotic metaphase cells was counted and expressed as the number per cell. Open circle, PBLs of patients with early stage; closed circle, that with advanced
stage. The line is the regression curve.
Table 2 Multivariate analysis of prognostic factors for disease-specific
survival
Variables Hazard ratio 95% CI P-value
Better
prognosis
Age 0.996 0.980–1.012 0.615
Surgery
Yes 0.382 0.159–0.919 0.032 Surgery
No 1
Cancer site
Breast+lymphoma 1
Others
a 2.055 0.882–4.786 0.095 Breast+lymphoma
Stage
Early 0.173 0.064–0.467 0.001 Early stage
Advanced 1
Chemoendocrinetherapy
Yes 0.949 0.557–1.617 0.848
No 1
DNA-PK activity 0.934 0.900–0.968 0.001 Higher DNA-PK
activity
Abbreviations: CI¼confidence interval; DNA-PK¼DNA-dependent protein kinase.
aUterine cervix, esophagus, and head and neck.
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metastasis-free survival.
The 5-year local control rate in early stage patients was 96.9%
with high DNA-PK activity and 100% with low DNA-PK activity,
whereas in advanced stage, it was 77.8% with high DNA-PK
activity and 71.3% with low DNA-PK activity. There was no
apparent correlation between local control rates with radiotherapy
and DNA-PK activity of PBLs.
In this analysis of spontaneous chromosomal aberrations in
PBLs at least one excess fragment was exhibited by each of the
30 patients (Figure 1D). There was a tendency of inverse correlation
between DNA-PK activity and excess fragments although this
correlation was not statistically significant. The frequency of excess
fragment increased as DNA-PK activity decreased in PBLs. The PBLs
of patients in advanced stages had the lower DNA-PK activity and
the higher frequency of excess fragments than those in early stages.
Figure 2A demonstrated the alterations of DNA-PK activity of PBLs
as a result of radiation in respect to the equivalent whole-body dose.
Each line indicates each patient and each marked point indicates
the sample that was obtained at a given equivalent whole-body
dose. The DNA-PK activity of PBLs in most patients decreased as
the equivalent whole-body dose increased.
Figure 2B demonstrated changes of DNA-PK activity and
protein levels of the components of DNA-PK genes (DNA-PKcs,
Ku70, and Ku86) in PBLs of two patients (O and T in Figure 2A)
treated with radiotherapy. DNA-PK activity and protein levels of
DNA-PKcs, Ku70, and Ku86 decreased as equivalent whole-body
doses increased.
Figure 2C showed the recovery of DNA-PK activity of PBLs after
radiotherapy. Zero month in time denotes the DNA-PK activity
measured before radiotherapy. The shaded zone in time indicates
periods of radiotherapy. DNA-PK activity of PBLs in most patients
was recovered after radiotherapy. However, the DNA-PK activity
of PBLs of two patients (patients B and F) did not recover at
23 months after radiotherapy.
DISCUSSION
We have previously illustrated that DNA-PK activity in PBLs
varied by a factor of 10 among the individual subjects, but the
difference in DNA-PK activity in PBLs was not explained by aging
or smoking history. DNA-PK activity can be influenced by the
abundance of DNA-PKcs, Ku86, and Ku70 (Someya et al, 2006). As
it is unyielding to evaluate the DNA-PK activity of infinitesimal of
tumour biopsy tissues specimens, we used PBLs for the purpose.
Auckley et al (2001) showed a tight correlation between DNA-PK
activity in PBLs and bronchial epithelial cells (a progenitor cell for
lung cancer) that were obtained by bronchoscopy, suggesting that
PBLs can be used as a substitute cell type.
Table 3 Multivariate analysis of prognostic factors for distant metastasis-
free survival
Variables Hazard ratio 95% CI P-value
Better
prognosis
Age 0.992 0.976–1.009 0.363
Surgery
Yes 0.415 0.182–0.945 0.036 Surgery
No 1
Cancer site
Breast+lymphoma 1
Others
a 1.904 0.827–4.387 0.130 Breast+lymphoma
Stage
Early 0.140 0.054–0.364 0.001 Early stage
Advanced 1
Chemoendocrinetherapy
Yes 0.918 0.542–1.554 0.749
No 1
DNA-PK activity 0.944 0.910–0.980 0.003 Higher DNA-PK
activity
Abbreviations: CI¼confidence interval; DNA-PK¼DNA-dependent protein kinase.
aUterine cervix, esophagus, and head and neck.
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Figure 2 (A) Changes of DNA-PK activity of PBLs after radiation
according to the equivalent whole-body dose. Each line indicated each
patient. Each point on each line indicated the sample that was obtained at a
given equivalent whole-body dose. (B) Alterations of DNA-PK activity and
protein levels of DNA-PK genes (DNA-PKcs, Ku70, and Ku86) in PBLs of
two patients (O and T in A) treated with radiotherapy. (C) Recovery of
DNA-PK activity of PBLs after radiotherapy. Zero month in time means the
DNA-PK activity before radiotherapy. The shaded zone in time indicates
periods of radiotherapy.
DNA-PK activity and prognosis of cancer
M Someya et al
1727
British Journal of Cancer (2011) 104(11), 1724–1729 & 2011 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sAggressive cancer phenotypes are a manifestation of many
different genetic alterations that promote rapid proliferation and
metastasis (Mironchik et al, 2005). Genomic instability promotes a
wide range of mutations, including chromosomal deletions, gene
amplifications, translocations, and polyploidy. It also prompts the
loss or activation of a number of critical genes, such as those
involved in cell proliferation, differentiation, and apoptosis
(Nishizaki et al, 1997; Maser and DePinho, 2002; Chin et al,
2004; Hezel et al, 2006). The repair of DSBs, the most potent
lesions, is vital for stable genome maintenance. Of these, DSBs are
believed to be one of the most lethal damages induced by DNA
damaging agents (Collis et al, 2005). Unrepaired DNA ends might
contribute to the development of chromosomal translocations by
acting as transposable elements (Hall, 2006a). Figure 1A demon-
strated that DNA-PK activities of PBLs in advanced cancer patients
were significantly lower than those in early cancer. Reduced DNA-
PK activity can profoundly affect the ability to repair DNA DSB,
resulting in the perpetuation of chromosome damage. Our results
substantiate that the lower DNA-PK activity is related with
chromosomal instability (Figure 1D). This may explain as to why
DNA-PK activities of PBLs in advanced cancer patients were
significantly lower than those in early stage.
We found that the patients with lower DNA-PK activity in PBLs
tended to have the lower survivals and higher rate of distant
metastasis than those with higher DNA-PK activity in advanced
stages, although the difference was not significant (Figures 1B and C).
This higher tendency of distant metastasis was the key factor of
their lower survival because there were no differences in local
control rates between lower and higher DNA activity. Genetic
instability related with low DNA-PK activity may cause higher
frequency of distant metastasis. These results indicated that low
DNA-PK activity in PBLs might be associated with aggressiveness
of cancer phenotypes such as advanced stages and higher tendency
of distant metastasis. As a result, DNA-PK activity in PBLs could
function as a marker to predict the chromosomal instability and
poorer prognosis to select individualised treatment for cancer.
There are several reports about expression of DNA-PK in varied
tumour tissues and prognosis of patients. Lee et al (2005, 2007)
reported that negative expression of DNA-PKcs in surgical
specimens was significantly associated with tumour progression
and poor patient survival rate in gastric cancers. Another report
stated that DNA-PK expression of tumour tissues is negatively
correlated with lymphatic metastasis, and the survival of patients
with colorectal cancer. They argued that Ku70 expression might be
a potential indicator for the preoperative evaluation, and prognosis
in colorectal cancer (Chen et al, 2008). These reports lead to
support our results obtained with PBLs if DNA-PK activity of PBLs
represents that of other kinds of cells.
Direct correlation between local control rates with radiotherapy
and DNA-PK activity of PBLs was not evident. Studies with cell
lines of rodent and human origin have demonstrated that the
absence of DNA-PK results in an exquisitely radiosensitive
phenotype and in a reduced ability to repair DNA (Jeggo, 1998).
However, dissimilar observations were made regarding whether
disparity in the levels of DNA-PK activity reflect the discrepancies
in inherent radiosensitivity of cell lines derived from human
tumours (Allaunis-Turner et al, 1995; Zhao et al, 2000). In
addition, it is unclear whether inherent radiosensitivity testing of
tumour specimens is predictive of the treatment response
(Allaunis-Turner et al, 1992; Taghian et al, 1993).
The DNA-PK activity along with the expressions of Ku70, Ku86,
and DNA-PKcs in PBLs of most patients decreased as the
equivalent whole-body dose increased (Figures 2A and B).
Especially the expression of DNA-PKcs markedly decreased. The
mechanism of transcriptional regulation of DNA-PK is not well
known. Therefore, it is also unknown whether reduced expression
of DNA-PKcs is compensated by increased expression of Ku 70 or
Ku86. However, compensation for DNA-PKcs by Ku proteins may
not be likely, as the role of DNA-PKcs is different from that of
Ku70 and Ku86 in DNA DSB repair (Lees-Miller, 1996; Jeggo,
1998).
Decreased DNA-PK activity of PBLs after radiotherapy was
recovered within several months in most of the patients. However,
in two patients, it did not recover even at 23 months after
radiotherapy (Figure 2C), which could be because of the protracted
suppression of expression of DNA-PKcs, Ku70, or Ku86. This
result suggests that DNA-PK activity of normal tissues may not
recover for long periods after exposure to irradiation. Normal cells
with protracted lowered DNA-PK activity after radiation exposure
may be susceptible to radiation-induced cancer. It has been
previously demonstrated by us that individuals with low DNA-PK
activity in PBLs had increased susceptibility to cancer, such as
breast and uterine cervix cancer (Someya et al, 2006). Intensity-
modulated radiation therapy (IMRT) has been recently prevailed
in clinical radiotherapy. A bigger volume of normal tissue can be
exposed to lower radiation doses with IMRT as compared with
other external radiation techniques. This is because IMRT
exercises more monitor units and, therefore, irradiates larger
equivalent whole-body doses (Hall, 2006b). Our results might
indicate the importance of low dose irradiation to normal tissues
in radiotherapy although its clinical meaning is not elucidated.
In summary, cancer patients with lower DNA-PK activity of
PBLs tended to have the higher distant metastasis and the poorer
prognosis, in advanced stage. DNA-PK activity in PBLs may thus
be used as a marker to possibly predict the chromosomal
instability and poorer prognosis in advanced stages patients only.
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